Coherus Oncology (CHRS) Tax Provisions (2019 - 2023)

Coherus Oncology (CHRS) has 3 years of Tax Provisions data on file, last reported at -$380000.0 in Q3 2023.

• For the quarter ending Q3 2023, Tax Provisions changed N/A year-over-year to -$380000.0; the trailing twelve-month figure through Dec 2023 stood at -$380000.0 (changed N/A YoY), and the FY2024 full-year result was $116000.0, up 130.53% from the prior year.
• Tax Provisions eased to -$380000.0 in Q3 2023, from $1.1 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $2.0 million in Q4 2019 to a low of -$380000.0 in Q3 2023.
• A 3-year average of $741625.0 and a median of $866500.0 in 2019 frame the typical range for Tax Provisions.
• Peak annual rise in Tax Provisions reached 2437.25% in 2020, while the deepest fall reached 77.12% in 2020.
• Tracing CHRS's Tax Provisions over 3 years: stood at $2.0 million in 2019, then tumbled by 47.4% to $1.1 million in 2020, then sank by 136.12% to -$380000.0 in 2023.
• Business Quant data shows CHRS's Tax Provisions at -$380000.0 in Q3 2023, $1.1 million in Q4 2020, and $183000.0 in Q3 2020.